|Jounce Therapeutics Inc -- USA Stock|| |
USD 24.52 0.58 2.31%
Dr. Thomas F. Gajewski, M.D. Ph.D. is a scientific cofounder of Jounce Therapeutics and currently serves as professor, departments of pathology and medicine, section of hematologyoncology at the University of Chicago. There, he is leader of the immunology and cancer program of the Cancer Center, and also directs the Melanoma Oncology Clinic. Dr. Gajewski is the immediate past president of the Society for Immunotherapy of Cancer and serves as an editor of Cancer Research and JITC. His laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote antitumor immunity in vivo. Dr. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies against the disease
Gajewski also leads development of immunebased therapies for other cancers, using new laboratory data on how the immune system is regulated to develop novel clinical trials. He has served on the program committees for the American Society for Clinical Oncology and the American Association for Cancer Research .
The company has return on total asset (ROA)
of (4.23) %
which means that it has lost $4.23 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (13.87) %
meaning that it created substantial loss on money invested by shareholders.
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics is traded on NASDAQ in USA.Jounce Therapeutics Inc (JNCE) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 112 people. Jounce Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.